• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS spectrums >Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)
【24h】

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

机译：日本重度抑郁症（MDD）患者的血清脑源性神经营养因子（BDNF），BDNF基因Val66Met多态性或血浆儿茶酚胺代谢产物以及对米氮平的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients. Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively. Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG). Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels. Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.
机译：目的。我们调查了日本重度抑郁症（MDD）患者的脑源性神经营养因子（BDNF）基因Val66Met多态性与对米氮平的反应之间的相关性。我们还检查了米氮平对这些患者血清BDNF和儿茶酚胺代谢产物血浆水平的影响。方法。符合DSM-IV-TR MDD标准的84名患者仅接受米氮平治疗4周。通过直接测序检测该区域的BDNF Val66Met多态性，并通过ELISA和HPLC-ECD分别测定血清BDNF水平和儿茶酚胺代谢产物的血浆水平。结果。米氮平治疗4周可显着增加反应者的血清BDNF水平，而无反应者则显着降低。在两种基因型（Val / Val与Met携带者）和T4时对米氮平的反应或T0时血清BDNF的水平之间均未发现关联。米氮平不会改变高香草酸（HVA）或3-甲氧基-4-羟基苯基乙二醇（MHPG）的血浆水平。讨论。血清BDNF水平的动态变化反映了对米氮平治疗的反应，但血浆HVA和MHPG水平没有变化。然而，抑郁症患者的BDNF Val66Met多态性与米氮平治疗的特定反应或基线血清BDNF水平均无关。结论。血清BDNF水平而非血浆HVA或MHPG水平以及BDNF Val66Met多态性与MDD中的米氮平反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号